Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.

Almasan A, Ashkenazi A.

Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48. Review.

PMID:
12787570
2.
3.

Apo2L/TRAIL and its death and decoy receptors.

LeBlanc HN, Ashkenazi A.

Cell Death Differ. 2003 Jan;10(1):66-75. Review.

4.

Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations.

Qin JZ, Bacon PE, Chaturvedi V, Bonish B, Nickoloff BJ.

Exp Dermatol. 2002 Dec;11(6):573-83.

PMID:
12473065
6.

Mechanisms of resistance to TRAIL-induced apoptosis in cancer.

Zhang L, Fang B.

Cancer Gene Ther. 2005 Mar;12(3):228-37. Review.

PMID:
15550937
7.

Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.

Aggarwal BB, Bhardwaj U, Takada Y.

Vitam Horm. 2004;67:453-83. Review.

PMID:
15110190
8.

TRAIL and apoptosis induction by TNF-family death receptors.

Wang S, El-Deiry WS.

Oncogene. 2003 Nov 24;22(53):8628-33. Review.

PMID:
14634624
9.

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.

Sayers TJ, Murphy WJ.

Cancer Immunol Immunother. 2006 Jan;55(1):76-84. Epub 2005 Oct 27. Review.

PMID:
15864587
10.

The complexity of TNF-related apoptosis-inducing ligand.

Abe K, Kurakin A, Mohseni-Maybodi M, Kay B, Khosravi-Far R.

Ann N Y Acad Sci. 2000;926:52-63. Review.

PMID:
11193041
11.

Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.

Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A.

J Biol Chem. 2005 Dec 9;280(49):40599-608. Epub 2005 Oct 15.

12.

Modulation of TRAIL signaling for cancer therapy.

Fulda S, Debatin KM.

Vitam Horm. 2004;67:275-90. Review.

PMID:
15110182
13.

FLIP protein and TRAIL-induced apoptosis.

Roth W, Reed JC.

Vitam Horm. 2004;67:189-206. Review.

PMID:
15110178
14.

TRAIL-induced signalling and apoptosis.

MacFarlane M.

Toxicol Lett. 2003 Apr 4;139(2-3):89-97. Review.

PMID:
12628743
15.

Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay.

Cillessen SA, Meijer CJ, Ossenkoppele GJ, Castricum KC, Westra AH, Niesten P, Muris JJ, Nijdam HF, van der Hem KG, Flens M, Hooijberg E, Oudejans JJ.

Br J Haematol. 2006 Aug;134(3):283-93.

PMID:
16848771
16.

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.

Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A.

J Biol Chem. 2005 Jan 21;280(3):2205-12. Epub 2004 Nov 1.

17.

Death to the bad guys: targeting cancer via Apo2L/TRAIL.

Bouralexis S, Findlay DM, Evdokiou A.

Apoptosis. 2005 Jan;10(1):35-51. Review.

PMID:
15711921
19.
20.

TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies.

Secchiero P, Vaccarezza M, Gonelli A, Zauli G.

Curr Pharm Des. 2004;10(29):3673-81. Review.

PMID:
15579063

Supplemental Content

Support Center